Analysts have raised their price target for Acutaas Chemicals from $1,466.17 to $1,516.33. They cite increased revenue growth expectations, despite a slightly lower projected profit margin and a modestly reduced future price-to-earnings ratio.
What's in the News
- The board meeting on October 17, 2025, will approve the unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2025 (Key Developments).
- The board meeting held on August 29, 2025, addressed the notice for the upcoming 18th annual general meeting scheduled for September 25, 2025, and considered the re-appointment of Mr. Nareshkumar Ramjibhai Patel as executive chairman and managing director from May 1, 2026 to April 30, 2031, subject to shareholder approval (Key Developments).
- The board meeting on July 30, 2025, focused on approving the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2025 (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has risen from ₹1,466.17 to ₹1,516.33.
- Discount Rate remains unchanged at 12.73%.
- Revenue Growth forecast increased from 30.67% to 33.05%.
- Net Profit Margin expectation decreased slightly from 17.88% to 17.58%.
- Future P/E ratio estimate has fallen from 45.17x to 41.94x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.